SGLT-2 inhibitors: Dapagliflozin is well tolerated in older individuals aged 75 years
|
|
- Arnold Richardson
- 5 years ago
- Views:
Transcription
1 Earn 3 CPD Points online SGLT-2 inhibitors: A perspective on safety and tolerability KEY MESSAGES Dapagliflozin is a new sodium glucose co-transporter-2 (SGLT-2) inhibitor for the treatment of type 2 diabetes It improves glycaemic control and is associated with additional beneficial effects, including a modest reduction in blood pressure, weight loss, low risk of hypoglycaemia and reduction in cardiovascular events Adverse renal effects of dapagliflozin have not been demonstrated, but because pharmacokinetics are altered by renal function, dapagliflozin is contraindicated in patients with an estimated glomerular filtration rate <60ml/min Adverse events related to volume depletion are uncommon in general, but are more likely to occur in patients 65 years of age. If they do occur, most are related to hypovolaemia, are mild/ moderate and do not require dose interruption or discontinuation Dapagliflozin is well tolerated in older individuals aged 75 years Type 2 diabetes is associated with an increased risk of non-sexually transmitted genital infections and SGLT-2 inhibitors increase this risk. Infections are usually responsive to the usual therapies. Patients should be warned about the risk and educated to be vigilant for symptoms, and to seek treatment if an infection occurs In patients with type 2 diabetes, diabetic ketoacidosis is a very rare adverse effect associated with SGLT-2 inhibitors. The risk can be minimised by careful patient selection and careful monitoring of patients at high risk. This report was made possible by an unrestricted educational grant from AstraZeneca. The content of the report is independent of the sponsor. The sodium glucose co-transporter-2 (SGLT-2) inhibitors (dapagliflozin, empagliflozin and canagliflozin) are a new class of drugs for the treatment of type 2 diabetes that has recently been introduced in South Africa. Inhibition of SGLT-2 increases renal glucose excretion in proportion to the amount of filtered glucose, which is, in turn, determined by the plasma glucose concentration and glomerular filtration rate (GFR). By blocking the action of SGLT-2, the SGLT-2 inhibitors promote glucose excretion and lower the renal threshold so that urinary glucose excretion occurs at a lower plasma glucose concentration. Because the mechanism of action of the SGLT-2 inhibitors is independent of insulin and their effect diminishes as plasma glucose concentrations decrease, they are associated with a low risk of hypoglycaemia. Furthermore, caloric loss associated with increased glucose excretion leads to a reduction in body weight and fat mass, and because SGLT-2 inhibitors have a mild diuretic effect, they are associated with a modest reduction in blood pressure. 1,2 Large randomised clinical trials and observational studies have shown that the SGLT-2 inhibitors are associated with a significant reduction in cardiovascular (CV) outcomes in patients with type 2 diabetes and this benefit is likely to be a class effect. 3-8 APRIL
2 Dapagliflozin In October 2017, dapagliflozin was the first SGLT-2 inhibitor to become available in South Africa for the treatment of type 2 diabetes. Its efficacy and safety have been well established in clinical studies in combination with metformin, a sulphonylurea, thiazolidinedione, a dipeptidyl Safety of SGLT-2 inhibitors Because the SGLT-2 inhibitors are a new class of treatment with a novel mechanism of action, their safety is of specific interest to medical practitioners. In general they have been shown to be well tolerated, without major safety concerns. However some adverse events, especially those related to the mechanism of action, including genital and urinary tract infections (UTIs), and urinary frequency, may be common. In addition, concern over Renal safety SGLT-2 inhibition increases glucose excretion by reducing its reabsorption in the proximal convoluted tubule of the kidney. The glomerulus is not involved, therefore sparing it from damage related to increased glucose load in that part of the nephron. Clinical trials of dapagliflozin have not demonstrated any adverse effects on renal function. Similar to that seen in clinical trials with empagliflozin, dapagliflozin was associated with an initial decline in estimated GFR (egfr) at week one (approximately -4ml/min), followed by a return towards baseline levels over 24 weeks that remained stable to week 102. Overall, over two years treatment with dapagliflozin, there was no evidence of new or worsening renal impairment, acute nephrotoxicity or progression of diabetic nephropathy. 12,14,19 In a fouryear comparison with glipizide, patients treated with dapagliflozin showed no consistent change in mean egfr, and values were above baseline at final follow-up. 10 The reversible decrease in egfr may Volume depletion Like the other SGLT-2 inhibitors, dapagliflozin causes glycosuria, which is associated with a mild osmotic diuretic effect that is limited to the kidney. It is therefore peptidase-4 (DPP-4) inhibitor (with and without metformin) and insulin. In these studies it was associated with significant reductions in HbA1c, and in fasting and postprandial glucose, an average of 2-4kg weight loss and a modest reduction in systolic blood pressure. 9,10 more serious adverse events emerging from early study results, some of which have not been confirmed by further studies and meta-analyses, nevertheless have resulted in the inclusion of warning and precautionary notes in the individual package inserts. 1,10-18 The following is a brief overview of current understanding of the safety and tolerability of these drugs, with special emphasis on the safety of dapagliflozin. be a beneficial effect related to transient changes in tubular-glomerular feedback mechanisms (causing renal glomerular afferent vasoconstriction), renal haemodynamics and intraglomerular pressure, resulting from diuresis, restricted reabsorption of sodium and reduction in blood pressure. 14,20 Indeed, in the EMPA- REG OUTCOME study, in comparison to placebo, empagliflozin was associated with a 39% reduction in incident or worsening nephropathy and slowed the expected natural progression of renal dysfunction. 21 The pharmacokinetics of dapagliflozin are affected by renal function. Although drug exposure is increased in patients with impaired renal function, the beneficial effects decline with increasing renal impairment. The drug should not be initiated in patients with moderate and severe renal impairment with an egfr <60ml/min, with end-stage renal failure or patients on dialysis. 19 unlike other osmotic diuretics such as mannitol, which increases osmotic pressure in blood vessels and therefore exerts an effect throughout all body tissues. This 2 APRIL 2018
3 diuresis is associated with small increases in urine volume of approximately ml per day over basal levels of l/day, approximately half to one-third that which would be expected with a thiazide or loop diuretic. 19,22 In an otherwise healthy patient with type 2 diabetes, normal responses, including thirst and secretion of antidiuretic hormone, would compensate for this effect and dehydration is unlikely to occur. Nevertheless, there is a theoretical potential for volume depletion in susceptible patients. In clinical studies of the SGLT-2 inhibitors, the incidence of volume depletion was low (approximately 2-3 per 100 patient years with empagliflozin and canagliflozin). In a pooled analysis of safety data from phase IIb/III clinical trials with dapagliflozin, the incidence of adverse events related to volume depletion (hypotension, hypovolaemia or dehydration) was 1.1% with dapagliflozin and 0.7% with placebo. In both groups, half of the adverse events occurred by week eight of treatment. In patients treated with dapagliflozin, hypovolaemia-related adverse events were more common in patients 65 Safety in older patients Type 2 diabetes is a common disease in older individuals, and the progressive decline in beta-cell function means that most elderly patients may require more complex treatment regimens. Furthermore, elderly patients are more likely to have comorbidities, multiple coprescribed medications and other risk factors that affect both the course of the illness and drug pharmacokinetics, and consequently, decisions about appropriate treatment (Table 1). A pooled analysis of phase IIb/III studies over up to 104 weeks has compared the safety of dapagliflozin in individuals <65 years, 65 years and 75 years. 25 Dapagliflozin was well tolerated in older patients with no difference in incidence of adverse events across the age groups (including hypoglycaemia), except for adverse events related to volume reduction and renal function, which were more common among elderly individuals (Table 2). Most of the adverse events related to renal function were small transient increases in serum creatinine. The incidence of serious adverse events was years of age, those on concurrent treatment with a loop diuretic (2.5-fold increase in risk) and patients with an egfr ml/min. The most common adverse event related to hypovolaemia was hypotension, but most events were considered unrelated to study drug, were mild/moderate in intensity and did not require dose interruption or discontinuation. 14 In studies of up to 104 weeks duration, adverse events of polyuria were reported in 4% and 1.4% of patients receiving dapagliflozin and placebo, respectively. The incidence of orthostatic hypotension did not change from baseline in either the dapagliflozin or placebo groups. Serious adverse events related to hypovolaemia up to 104 weeks were reported in 0.2% patients receiving dapagliflozin and 0.3% receiving placebo. 22 From a practical point of view, volume depletion should be assessed before initiating treatment with an SGLT-2 inhibitor. The drugs are not recommended for patients at risk of hypotension, such as those who are volume-depleted or who are receiving loop diuretics. 20 Table 1. Risk factors and comorbidities in elderly patients with type 2 diabetes Co-existing illnesses 2. Multiple medications 3. Reduced insulin secretion and increased insulin resistance 4. Increased risk for and severity of diabetes complications 5. Reduced lean mass (sarcopenia) 6. Increased adipose tissue 7. Decreased physical activity 8. Poor nutrition 9. Altered fluid status (e.g. due to medications (corticosteroids, diuretics), insufficient fluid intake) 10. Cognitive impairment, depression, dementia 11. Increased risk for hypoglycaemia 12. Increased risk for falls and fractures 13. Increased risk for hypotension and CV events 14. Poor vision and hearing APRIL
4 similar across age groups and was comparable with placebo. Dapagliflozin was not associated with an increased risk of fractures, falls or CV events. 5,25 Table 2. Incidence of adverse events with dapagliflozin among patients in different age groups 25 Age <65 years Age 65 years Age 75 years Adverse events Dapagliflozin Placebo Dapagliflozin Placebo Dapagliflozin Placebo (n=1406) (n=1301) (n=620) (n=655) (n=97) (n=77) All adverse events 73% 71% 77% 73% 80% 75% Discontinuation 6% 5% 14% 12% 27% 22% Serious adverse event 11% 12% 20% 20% 20% 18% Hypoglycaemia 18% 13% 20% 18% 17% 17% UTI 9% 5% 8% 8% 8% 9% Genital infection 8% 1% 7% 1% 7% 0% Volume reduction 2% 1% 2% 2% 3% 3% Renal function adverse event 3% 2% 14% 8% 30% 21% Because of the potential for weight loss, dehydration, hypotension, acute kidney injury and fungal genital infections, the 2017 SEMDSA guidelines for the Hypoglycaemia In patients with type 2 diabetes, hypoglycaemia adversely affects quality of life and adherence to treatment regimens, and is associated with an increased risk of CV events. Because the mechanism of action of the SGLT-2 inhibitors is independent of secretion or action of insulin and their effect diminishes as plasma glucose concentrations decrease, they are associated with a low risk of hypoglycaemia. 1 In a pooled analysis of phase IIb/III studies over up to 104 weeks, the incidence of hypoglycaemia was 13.7% and 12.4% with dapagliflozin (n=2295, 958 patients years) and placebo (n=2360, 998 patients years), respectively. 14 In a four-year study UTIs and genital infections Due to elevated urinary glucose, increased bacterial growth and increased adherence of bacteria to the uroepithelium, patients with diabetes are at increased risk of UTIs and non-sexually transmitted genital infections (vulvovaginitis and balanitis). Because they increase renal glucose excretion, the SGLT-2 inhibitors may cause treatment of type 2 diabetes recommend that SGLT-2 inhibitors be avoided in frail elderly individuals. comparing dapagliflozin with glipizide in patients with type 2 diabetes, dapagliflozin was associated with a 10-fold lower incidence of hypoglycaemic events (5% vs 52%, respectively). 26 The frequency of hypoglycaemia with dapagliflozin appears to be dependent on the background therapy to which it is added. No major episodes of hypoglycaemia occurred with dapagliflozin monotherapy. Severe hypoglycaemia with dapagliflozin is rare and was mainly observed in patients receiving concomitant treatment with a sulphonylurea or insulin. 14,20,27 additional growth of commensal genital microorganisms and two of the most commonly reported adverse events in SGLT-2 inhibitor trials were UTIs and genital infections, both of which occurred significantly more commonly than with placebo. 20,28 The increased risk of UTI with SGLT-2 inhibitors appears to be small. In a pooled 4 APRIL 2018
5 analysis of dapagliflozin trials the occurrence of UTI was 4.7% with dapagliflozin and 3.5% with placebo. UTIs were more common in women than in men and most were mild/moderate in intensity, responding well to initial antimicrobial treatment. 14 To reduce the risk of UTI, patients should be advised to maintain adequate hydration and careful bathroom hygiene and to seek medical care if they experience symptoms. 23 However, the true significance of SGLT-2 inhibitor-associated UTIs is uncertain. Because of the mechanism of action, UTIs were closely monitored in clinical trials and, in addition to the increase in benign urinary symptoms that may occur with these drugs (e.g. increased urinary output), they may have been overreported. 28 It is interesting to note that a recent meta-analysis of SGLT-2 inhibitor Malignancy Meta-analyses of clinical studies have not demonstrated a significant increase in overall risk of cancer with SGLT-2 inhibitors Early reports that dapagliflozin might be associated with an increased incidence of breast or bladder cancer have not been validated and recent data suggest that the imbalance in the occurrence of cancers observed in clinical studies might be due to early diagnosis of pre-existing Fractures and amputations In the Canagliflozin Cardiovascular Assessment (CANVAS) programme, canagliflozin was associated with a small risk of both fractures and amputations (primarily at the level of the toe or metatarsal). 4 These observations are confined to CANVAS and risk of fractures was studies failed to demonstrate any increase in risk of UTI associated with this class of medication. 29 Pyelonephritis is not increased with SGLT-2 inhibitor treatment. 14,28 Genital infections were more frequent with dapagliflozin than with placebo (5.5% vs 0.6%), with no clear dose relationship. 14 They were more common in women (vulvovaginitis) than in men (balanitis), were mild to moderate in severity and responded to initial antimicrobial therapy. Patients with a history of recurrent genital yeast infections were more likely to be diagnosed with genital infection than those without. Most infections occurred early in the course of treatment and recurrence was uncommon. 28 The frequency of genital infections was similar in clinical trials of empagliflozin and canagliflozin. 20 neoplasms rather than a real increase in cancer incidence. 31 As a precautionary measure, the European Medicines Agency and the 2017 SEMDSA recommend that dapagliflozin not be prescribed to patients with bladder cancer or in combination with pioglitazone, which has been linked to a small, but non-significant risk of bladder cancer. 19,23 not increased in a pooled analysis of non- CANVAS studies. 33 Nevertheless, the US Food and Drug Administration (FDA) has issued safety alerts for both of these adverse events and requested that the prescribing information for canagliflozin be updated accordingly. 16,18 Diabetic ketoacidosis (DKA) DKA is a sometimes life-threatening complication of diabetes. It occurs consequent to severe insulin deficiency, most commonly in poorly controlled type 1 diabetes, or in patients with type 2 diabetes who are subject to stressors, such as infection, injury or surgery. Although it is usually associated with marked hyperglycaemia and dehydration, less commonly it can occur with only moderately elevated or even normal levels of plasma glucose (euglycaemic DKA). The SGLT-2 inhibitors have been associated with uncommon cases of DKA, including euglycaemic DKA. It is possible that euglycaemic DKA may occur as a result of drug-induced glycosuria with consequent decline in both plasma glucose and circulating insulin. The low level of insulin promotes production of free fatty acids, which undergo beta-oxidation and conversion to ketone bodies in the liver. APRIL
6 Ketone production is also potentiated by an increase in glucagon secretion. Glycosuria prevents the plasma glucose from increasing to the excessive levels normally seen in DKA, which further aggravates low levels of insulin secretion. The clinical importance of euglycaemic DKA is that, because it is not necessarily associated with the typical clinical manifestations of DKA, such as dehydration induced by marked hyperglycaemia, diagnosis and treatment may be delayed, allowing progressive metabolic deterioration. Severe acidosis alone has the potential to become life-threatening. 34,35 The risk of DKA with SGLT-2 inhibitors is greatest in patients with type 1 diabetes, in whom they should be avoided. Factors that might increase the risk of euglycaemic DKA in patients with type 2 diabetes are listed in Table 3. In a recent review of patient outcomes from a large claims database in the USA, the incidence of DKA over 180 days follow-up among patients not receiving insulin was 2.5 and 1.0 per 1000 patient years for SGLT-2 inhibitors and DPP-4 inhibitors, respectively (odds ratio 2.5; 95% CI ). 36 In an analysis of the FDA Adverse Event Reporting System (FAERS) up until September 2016, in a heterogeneous group of patients including those with type 1 or type 2 diabetes, there were more than 2500 reports of DKA in which SGLT-2 inhibitors were listed as suspect or concomitant drugs. However, only 1.5% of cases were fatal. 37 In phase IIb/III clinical trials with dapagliflozin the estimated incidence of DKA or metabolic acidosis was 0.03% and the estimated incidence of DKA alone was 0.02%. 14 Patients for whom SGLT-2 inhibitors are prescribed and who have risk factors for DKA should be carefully monitored. Regardless of current plasma glucose levels, any patient who is being treated with an SGLT-2 inhibitor and who feels unwell (e.g. malaise, nausea, vomiting) should be investigated for ketonuria and ketonaemia. Table 3. Risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetes 35 Long-standing diabetes (severe beta-cell deficiency) Reduced insulin doses (in insulin dependent diabetes) Intercurrent illness Reduced food and fluid intake (prolonged starvation; low carbohydrate diets) After surgery Alcohol CV safety The SGLT-2 inhibitors are associated with a modest reduction in blood pressure of around 3-5mmHg. In diabetic patients with hypertension, placebo-corrected changes in blood pressure with dapagliflozin were -3.6 and -1.2mmHg for systolic and diastolic blood pressure, respectively. These benefits are not associated with an increase in heart rate or an increase in orthostatic hypotension. 20 In a large safety analysis of dapagliflozin studies, the incidence of syncope on treatment remained consistently lower than in the placebo group ( 0.2% vs 0.5% respectively) across all age groups, including among patients aged 75 years and older. 25 In randomised placebo-controlled studies, treatment with both empagliflozin and canagliflozin was associated with a reduced incidence of major adverse CV events (MACE) and hospitalisation for heart failure in patients with type 2 diabetes at high risk for CV events who were already treated with standard care, including other glucose-lowering agents, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, antithrombotic agents and statins. 3,4 Empagliflozin was also associated with a reduction in CV death. 3 Large meta-analyses and observational studies have indicated that this beneficial class effect also extends to dapagliflozin. 5-7 In an analysis of data from a large multinational observational study (CVD-REAL Nordic), CV outcomes were compared for new users of dapagliflozin (n=10 227) versus new users of DPP-4 inhibitors (n=30 681), among whom 23% had established CV disease at baseline. Treatment with dapagliflozin was associated with a significantly lower risk of MACE, hospitalisation for heart 6 APRIL 2018
7 failure and all-cause mortality (21%, 38% and 41% lower risk, respectively). 7 The CV safety of dapagliflozin is also the subject of a large ongoing randomised placebocontrolled trial, DECLARE. DECLARE will assess CV outcomes in a broad population of more than patients with type 2 diabetes and established CV disease or multiple CV risk factors. Results Conclusions Rather than merely to achieve glycaemic targets, the aim of diabetes management is to reduce the burden of premature morbidity and mortality associated with the disease. 23 With that in mind, the SGLT-2 inhibitors are an exciting new addition to the treatment options available to clinicians and their patients. In addition to helping achieve glycaemic targets, they have the potential to reduce both CV mortality and morbidity and improve quality of life in a diverse range of patients. 4-8 References 1. Vivian EM. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs in Context 2014; 3: Published online. DOI: /dic Bays H. Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther 2013; 4: Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 2015; 373: Neal B, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a metaanalysis. Cardiovasc Diabetol 2016; 15: 37. Published online. DOI /s y 6. Birkeland K, Jørgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 2017; 5(9): Persson F, Nyström T, Jørgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab Published online. DOI: /dom Wu JH, Foote C, Blomster J, et al. Effects of sodiumglucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016; 4(5): Daniel D, Bray N. A medical literature review on canagliflozin and dapagliflozin and the role of SGLT2 inhibitors in diabetic management. J Sci Technol 2015; 3: Published online. DOI: /2015/ Del Prato S, Nauck M, Durán-Garcia S, et al. Long-term are expected in The exact mechanisms behind the beneficial CV effects of the SGLT-2 inhibitors are uncertain. However, possible contributory factors include the osmotic diuretic effect, improvement in glycaemic control and blood pressure, reduced blood volume and sodium retention, reduction in arterial stiffness and weight loss. 20 Overall, they are well tolerated with the incidence of most adverse events being comparable with placebo. More common adverse events, including genital infections, are easily managed and serious adverse events are rare. Careful patient selection and ongoing monitoring, as should be the usual standard of care for patients with type 2 diabetes, will help to ensure that patients receive the maximum benefit from this new class of treatments. glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 2015; 17: McGovern AP, Dutta N, Munro N, et al. Dapagliflozin: Clinical practice compared with pre-registration trial data. Br J Diabetes Vasc Dis 2014; 14: Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol 2015; 14: 142. Published online. DOI: /s x. 13. Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: a systematic review and network meta-analysis. Diabetes Obes Metab 2016; 18: Jabbour S, Seufert J, Scheen A, et al. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab Published online. DOI: / dom US Food and Drug Administration (FDA). FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Drug Saf Comm May 15; Accessed 30 October US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Accessed 30 October US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). Accessed 30 October US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information APRIL
8 on decreased bone mineral density. gov/drugs/drugsafety/ucm htm. Accessed 30 October Anderson SL. Dapagliflozin efficacy and safety: a perspective review. Ther Adv Drug Saf 2014; 5(6): Dandona P, Chaudhuri A. Sodium-glucose co-transporter inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. Int J Clin Pract 2017; 71: e Published online. DOI: /ijcp Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: Johnsson K, Johnsson E, Mansfield TA, et al. Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin trials. Postgrad Med Published online. DOI: / The Society for Endocrinology, Metabolism and Diabetes of South Africa Type 2 Diabetes Guidelines Expert Committee. The 2017 SEMDSA Guideline for the Management of Type 2 Diabetes Guideline Committee. JEMDSA 2017; 21(1) (Supplement 1): S1-S Wooten JM. Pharmacotherapy considerations in elderly adults. South Med J 2012; 105(8): Fioretto P, Mansfield TA, Ptaszynska A, et al. Longterm safety of dapagliflozin in older patients with type 2 diabetes mellitus: a pooled analysis of phase IIb/III studies. Drugs Aging 2016; 33: Del Prato S, Nauck M, Durán-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 2015; 17: Matthaei S, Bowering K, Rohwedder K, et al. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 2015; 38: Geerlings S, Fonseca V, Castro-Diaz D, et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glycosuria. Diabetes Res Clin Pract 2014; 103: Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep 2017; Published online. DOI: /s w 30. Ptaszynska A, Johnsson KM, Parikh SJ, et al. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf 2014; 37(10): Lin H-W, Tseng C-H. A review of the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol 2014: Published online. DOI: /2014/ Tang H, Dai Q, Shi W, et al. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and metaanalysis of randomised controlled trials. Diabetologia 2017; 60: Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016; 101: Ogawa W, Sakaguchi K. Euglyceamic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diab Invest 2016; 7(2): Rosenstock J, Ferannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 38: Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017; 376(23): Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia Published online. DOI: /s This article is based on presentations at the AstraZeneca Connecting the Experts in Diabetes Forum, held in Somerset West in October Speakers included Dr Aslam Amod, Dr Joel Dave, Prof James Gavin, Dr Daksha Jivan, Dr Duma Khutsoane, Dr Helena Oosthuizen, Dr Hoosen Randeree, Prof Brian Rayner, Dr Sundeep Ruder and Dr Zane Stevens. The article was written for DeNovoMedica.com by Dr David Webb. Earn CPD points online Visit Log in or register and start earning CPD points today. Certificates will be ed to you. Disclaimer The views and opinions expressed in the article are those of the presenters and do not necessarily reflect those of the publisher or its sponsor. In all clinical instances, medical practitioners are referred to the product insert documentation as approved by relevant control authorities. Published by 70 Arlington Street, Everglen, Cape Town, 7550 Tel: (021) I info@denovomedica.com 8 APRIL 2018
Dapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.19 Subject: SGLT2 Inhibitors Page: 1 of 6 Last Review Date: September 15, 2016 SGLT2 Inhibitors Description
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.19 Subject: SGLT2 Inhibitors Page: 1 of 5 Last Review Date: December 3, 2015 SGLT2 Inhibitors Description
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationStudy Design: Prospective, Multicenter randomized, parallel-group, double blind, placebo controlled study.
Brand Name: Farxiga Generic Name: Dapagliflozin Manufacturer: Astra-Zenica Drug Class 1,2 : Antidiabetic agent, SGLT2 Inhibitor Uses: Labeled Uses 1,2,3,4 : Improving glycemic control in adults with type
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationDrug Class Review Monograph GPI Class 27 Anti-diabetics
Drug Class Review Monograph GPI Class 27 Anti-diabetics Review Time Frame: 11/2015 04/2017 Previous Class Review: 02/2016 Background: Antidiabetic drug classes include: Alpha-glucosidase inhibitors- slow
More informationpremix insulin and DPP-4 inhibitors what are the facts? New Sit2Mix trial provides first global evidence
Earn 3 CPD Points online Using a premix insulin (BIAsp 30) with a DPP-4 inhibitor what are the facts? New Sit2Mix trial provides first global evidence An important trial using a premix insulin (BIAsp 30)
More informationPRODUCT MONOGRAPH INVOKANA. canagliflozin tablets. 100 mg and 300 mg as anhydrous canagliflozin
PRODUCT MONOGRAPH Pr canagliflozin tablets 100 mg and 300 mg as anhydrous canagliflozin ATC Code: A10BK02 Other blood glucose lowering drugs, excl. insulins Janssen Inc. 19 Green Belt Drive Toronto, Ontario
More informationSummary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin)
EMA/217413/2015 Summary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin) This is a summary of the risk management plan (RMP) for Synjardy, which details the measures to be taken
More informationShort-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting
Singapore Med J 2018; 59(5): 251-256 https://doi.org/10.11622/smedj.2017095 Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationIt is well understood that patients with type 2 diabetes (T2D) are
INFORMATION for the PHARMACIST This article was sponsored by Boehringer Ingelheim and Lilly. Addressing the Risk of Cardiovascular Mortality in Adult Patients with Type 2 Diabetes and Established Cardiovascular
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationSGLT2 Inhibitors. Vijay Negalur
C H A P T E R 173 SGLT2 Inhibitors Vijay Negalur INTRODUCTION Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by hyperglycemia that results from insulin resistance, diminished
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationSodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
Editorial Page 1 of 5 Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes Hidekatsu Yanai Department of Internal Medicine, National Center for Global Health and Medicine
More information1. Pharmacokinetics. When is steady state achieved? Steady-state was reached after 4 to 5 days of once-daily dosing with Sulisent 100 mg to 300mg.
1. Pharmacokinetics How is Sulisent metabolized? Sulisent has a novel mechanism of action that targets the kidneys and allows for excess glucose excretion resulting in urinary calorie loss. Sulisent is
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationPRODUCT MONOGRAPH INVOKANA. canagliflozin tablets. 100 mg and 300 mg as anhydrous canagliflozin
PRODUCT MONOGRAPH Pr canagliflozin tablets 100 mg and 300 mg as anhydrous canagliflozin ATC Code: A10BK02 Other blood glucose lowering drugs, excl. insulins Janssen Inc. 19 Green Belt Drive Toronto, Ontario
More informationSodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview
Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview Juan F. Mosley II, PharmD, CPh, AAHIVP; Lillian Smith, PharmD, CPh, MBA; Emily Everton,
More informationSGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk
Managing Diabetes & CVD: Expling New Evidence & Opptunities ESC Congress, London, UK 30 August, 2015 SGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk Silvio E. Inzucchi MD Yale
More informationInternational Diabetes Federation
40 Original Article A Prospective Analysis of the Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors: Real World Evidence from Clinical Practice in India Bhavana Sosale 1, Aravind R Sosale
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION INVOKAMET
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr INVOKAMET canagliflozin and metformin hydrochloride tablets (canagliflozin (as anhydrous canagliflozin) and metformin hydrochloride) 50 mg/500
More informationChallenges in type 2 diabetes control: slipping control and weight gain
control Earn 3 CPD Points online Case study Challenges in type 2 diabetes control: slipping control and weight gain Presenter Dr Sedeshan Govender Specialist Physician, Endocrinologist and Diabetologists
More informationSummary of the risk management plan (RMP) for Vokanamet (canagliflozin / metformin)
EMA/137565/2014 Summary of the risk management plan (RMP) for Vokanamet (canagliflozin / metformin) This is a summary of the risk management plan (RMP) for Vokanamet, which details the measures to be taken
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationPRODUCT MONOGRAPH FORXIGA
PRODUCT MONOGRAPH dapagliflozin tablets (as dapagliflozin propanediol monohydrate) 5 mg and 10 mg ATC Code: A10BK01 Sodium-glucose co-transporter 2 (SGLT2) inhibitors AstraZeneca Canada Inc. 1004 Middlegate
More informationSESSION 4 12:30pm 1:45pm
SESSION 4 12:30pm 1:45pm Addressing Renal-Mediated Glucose Homeostasis: Diabetes and the Kidney SPEAKER Davida Kruger, MSN, BC-ADM, APRN Presenter Disclosure Information The following relationships exist
More informationOver 90% of people with type 2
Article The new class war: SGLT2 inhibitors versus DPP-4 inhibitors Merlin Thomas Over 90% of people with type 2 diabetes will need more than metformin monotherapy to achieve their targets for optimal
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationHave you seen a patient like Carol *?
(linagliptin) 5mg tablets Have you seen a patient like Carol *? *Hypothetical patient profile Carol * : 70 years old Retired schoolteacher *Hypothetical patient profile CAROL*: T2D patient with moderate
More informationAUSTRALIAN PRODUCT INFORMATION - JARDIANCE empagliflozin film-coated tablets
AUSTRALIAN PRODUCT INFORMATION - JARDIANCE empagliflozin film-coated tablets 1 NAME OF THE MEDICINE empagliflozin 2 QUALITATIVE AND QUANTITATIVE COMPOSITION JARDIANCE 10 mg film-coated tablets contains
More informationEffects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis
Elmer ress Original Article J Clin Med Res. 2016;8(3):237-243 Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis Hisayuki
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Invokana 100 mg film-coated tablets Invokana 300 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Invokana
More informationTechnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418
Dapagliflozin in triple therapy for treating type 2 diabetes Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418 NICE 2018. All rights reserved. Subject to Notice of rights
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More information*Sections or subsections omitted from the full prescribing information are not listed.
US-13287 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XIGDUO XR safely and effectively. See full prescribing information for XIGDUO XR. XIGDUO
More informationAUSTRALIAN PRODUCT INFORMATION GLYXAMBI empagliflozin and linagliptin filmcoated
AUSTRALIAN PRODUCT INFORMATION GLYXAMBI empagliflozin and linagliptin filmcoated tablets 1 NAME OF THE MEDICINE empagliflozin and linagliptin 2 QUALITATIVE AND QUANTITATIVE COMPOSITION GLYXAMBI are film-coated
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationPRESCRIBING INFORMATION (PI)
PRESCRIBING INFORMATION (PI) BYDUREON 2 MG POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION IN PRE-FILLED PEN (exenatide) BYETTA (exenatide) 5 MICROGRAMS AND 10 MICROGRAMS SOLUTION FOR
More informationLower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10
6 Diabetes Care Volume 41, January 2018 PERSPECTIVES IN CARE Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10 https://doi.org/10.2337/dc17-1223
More informationSGLT2 Inhibitors From Discovery to Clinical Practice
SGLT2 Inhibitors From Discovery to Clinical Practice Sunder Mudaliar, MD, FRCP (Edin), FACP, FACE Clinical Professor of Medicine University of California, San Diego Staff Physician VA San Diego Healthcare
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationGLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.
GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationCase study: Lean adult with no complications, newly diagnosed with type 2 diabetes
Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The
More informationThe Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs
The Role Of SGLT-2 Inhibitors In Clinical Practice Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest Consultantship
More informationNorthern California Chapter ACP Update In Medicine I
Northern California Chapter ACP Update In Medicine I Kurt M. Hafer MD, FACP Clinical Assistant Professor Stanford University School of Medicine Division of Primary Care and Population Health November 3,
More informationStudy Duration (Weeks) Reference Number
Supplementary Table 1. SGLT2 Inhibitor Monotherapy SGLT2 Inhibitor vs /Comparator Canagliflozin 100 mg Canagliflozin 300 mg 26 26 (n) 195 197 in 0.91 1.16 in FPG 36.0 43.2 Canagliflozin 100 mg Canagliflozin
More informationPRESCRIBING INFORMATION (PI)
PRESCRIBING INFORMATION (PI) BYDUREON (exenatide) 2MG POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION BYETTA (exenatide) 5 MICROGRAMS AND 10 MICROGRAMS SOLUTION FOR INJECTION, PREFILLED
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Forxiga 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains dapagliflozin propanediol
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationTechnology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta288
Dapagliflozin in combination therapy for treating type 2 diabetes Technology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta288 NICE 2018. All rights reserved. Subject to Notice of rights
More informationSummary of Risk Management Plan for VOKANAMET (Canagliflozin/Metformin Hydrochloride Fixed Dose Combination)
Summary of Risk Management Plan for VOKANAMET (Canagliflozin/Metformin Hydrochloride Fixed Dose Combination) This is a summary of the risk management plan (RMP) for VOKANAMET. The RMP details important
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationAmbrish Mithal MD, DM
Ambrish Mithal MD, DM Chairman, Division of Endocrinology and Diabetes Medanta The Medicity Padma Bhushan Awardee 2015, Member Governing Council, Indian Council of Medical Research (ICMR) Dr Mithal is
More informationManaging patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationDifferentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes
Differentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes Eden M. Miller, DO; Carol H. Wysham, MD CONTINUING MEDICAL EDUCATION LEARNING OBJECTIVES Provide an overview
More informationBrand name: Steglatro. Generic name: Ertugliflozin (er too gli FLOE zin) Manufacturer: Merck
Brand name: Steglatro Generic name: Ertugliflozin (er too gli FLOE zin) Manufacturer: Merck Drug Class: Sodium-glucose co-transporter 2 (SGLT2) inhibitor Uses: Labeled: Indicated as adjunct to diet and
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION GLYXAMBI TM. empagliflozin and linagliptin tablets. 10 mg/5 mg and 25 mg/5 mg
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr GLYXAMBI TM empagliflozin and linagliptin tablets 10 mg/5 mg and 25 mg/5 mg ATC Code: A10BD19 Combinations of oral blood glucose lowering drugs
More informationDPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
THERAPY REVIEW DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes STEVE CHAPLIN SPL DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixeddose
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationINVOKAMET (canagliflozin and metformin hydrochloride) tablets for oral use
INVOKAMET (canagliflozin and metformin hydrochloride) tablets for oral use Revised: 08/2017 084131-171109 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed
More informationIs an SGLT2 inhibitor right for your patient with type 2 diabetes?
Is an SGLT2 inhibitor right for your patient with type 2 diabetes? Metformin isn t quite doing the job or is contraindicated? Here s a look at the patients who may benefit from these agents and the monitoring
More informationJARDIANCE PRODUCT MONOGRAPH. empagliflozin tablets. 10 mg and 25 mg. ATC Code: A10BK03 Sodium-glucose co-transporter 2 (SGLT2) inhibitors
PRODUCT MONOGRAPH Pr JARDIANCE empagliflozin tablets 10 mg and 25 mg ATC Code: A10BK03 Sodium-glucose co-transporter 2 (SGLT2) inhibitors Boehringer Ingelheim (Canada) Ltd 5180 South Service Rd Burlington,
More informationPeter Stein, MD Janssen Research and Development
New Agents and Technologies in the Pipeline for the Treatment of Patients with Diabetes Peter Stein, MD Janssen Research and Development Agents in Phase 3 Development for T2DM Long-acting GLP-1 analogues
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationINVOKAMET XR (canagliflozin and metformin hydrochloride extended-release)
INVOKAMET XR (canagliflozin and metformin hydrochloride extended-release) tablets, for oral use Revised: 07/2017 076317-170714 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all
More informationSGLT-2 INHIBITORS: CVD REDUCTION THROUGH DIURESIS
SGLT-2 INHIBITORS: CVD REDUCTION THROUGH DIURESIS Dr. Kirtida Acharya National chair, Diabetes Kenya Consultant Endocrinologist/Diabetologist, MP Shah Hospital KCS Symposium, 30 th June, 2017 Sarova Whitesands,
More informationCanagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin in combination therapy for treating type 2 Issued: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Choosing the Right Agent for your Patient with diabetes: Individualizing type 2 diabetes management in light of the expanding therapies
More information